Triple-S Management Corporation

GTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GTS stands at 0. In comparison, UNH has a market cap of 321.9B. Regarding current trading prices, GTS is priced at $35.99, while UNH trades at $367.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GTS currently has a P/E ratio of 10.41, whereas UNH's P/E ratio is 26.81. In terms of profitability, GTS's ROE is +0.07%, compared to UNH's ROE of +0.12%. Regarding short-term risk, GTS is less volatile compared to UNH. This indicates potentially lower risk in terms of short-term price fluctuations for GTS.Check UNH's competition here

GTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GTS stands at 0. In comparison, ANTM has a market cap of 114.6B. Regarding current trading prices, GTS is priced at $35.99, while ANTM trades at $482.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GTS currently has a P/E ratio of 10.41, whereas ANTM's P/E ratio is 18.99. In terms of profitability, GTS's ROE is +0.07%, compared to ANTM's ROE of +0.12%. Regarding short-term risk, GTS is less volatile compared to ANTM. This indicates potentially lower risk in terms of short-term price fluctuations for GTS.Check ANTM's competition here

GTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GTS stands at 0. In comparison, CVS has a market cap of 100.5B. Regarding current trading prices, GTS is priced at $35.99, while CVS trades at $81.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GTS currently has a P/E ratio of 10.41, whereas CVS's P/E ratio is 56.39. In terms of profitability, GTS's ROE is +0.07%, compared to CVS's ROE of +0.02%. Regarding short-term risk, GTS is less volatile compared to CVS. This indicates potentially lower risk in terms of short-term price fluctuations for GTS.Check CVS's competition here

GTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GTS stands at 0. In comparison, ELV has a market cap of 77.4B. Regarding current trading prices, GTS is priced at $35.99, while ELV trades at $364.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GTS currently has a P/E ratio of 10.41, whereas ELV's P/E ratio is 15.08. In terms of profitability, GTS's ROE is +0.07%, compared to ELV's ROE of +0.12%. Regarding short-term risk, GTS is less volatile compared to ELV. This indicates potentially lower risk in terms of short-term price fluctuations for GTS.Check ELV's competition here

GTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GTS stands at 0. In comparison, CI has a market cap of 74.5B. Regarding current trading prices, GTS is priced at $35.99, while CI trades at $285.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GTS currently has a P/E ratio of 10.41, whereas CI's P/E ratio is 12.74. In terms of profitability, GTS's ROE is +0.07%, compared to CI's ROE of +0.15%. Regarding short-term risk, GTS is less volatile compared to CI. This indicates potentially lower risk in terms of short-term price fluctuations for GTS.Check CI's competition here

GTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GTS stands at 0. In comparison, HUM has a market cap of 26.9B. Regarding current trading prices, GTS is priced at $35.99, while HUM trades at $231.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GTS currently has a P/E ratio of 10.41, whereas HUM's P/E ratio is 22.73. In terms of profitability, GTS's ROE is +0.07%, compared to HUM's ROE of +0.07%. Regarding short-term risk, GTS is less volatile compared to HUM. This indicates potentially lower risk in terms of short-term price fluctuations for GTS.Check HUM's competition here

GTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GTS stands at 0. In comparison, CNC has a market cap of 21.4B. Regarding current trading prices, GTS is priced at $35.99, while CNC trades at $48.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GTS currently has a P/E ratio of 10.41, whereas CNC's P/E ratio is -3.22. In terms of profitability, GTS's ROE is +0.07%, compared to CNC's ROE of -0.28%. Regarding short-term risk, GTS is less volatile compared to CNC. This indicates potentially lower risk in terms of short-term price fluctuations for GTS.Check CNC's competition here

GTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GTS stands at 0. In comparison, MOH has a market cap of 9.3B. Regarding current trading prices, GTS is priced at $35.99, while MOH trades at $188.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GTS currently has a P/E ratio of 10.41, whereas MOH's P/E ratio is 48.09. In terms of profitability, GTS's ROE is +0.07%, compared to MOH's ROE of +0.04%. Regarding short-term risk, GTS is less volatile compared to MOH. This indicates potentially lower risk in terms of short-term price fluctuations for GTS.Check MOH's competition here

GTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GTS stands at 0. In comparison, OSCR has a market cap of 4.5B. Regarding current trading prices, GTS is priced at $35.99, while OSCR trades at $17.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GTS currently has a P/E ratio of 10.41, whereas OSCR's P/E ratio is -10.17. In terms of profitability, GTS's ROE is +0.07%, compared to OSCR's ROE of -0.39%. Regarding short-term risk, GTS is less volatile compared to OSCR. This indicates potentially lower risk in terms of short-term price fluctuations for GTS.Check OSCR's competition here

GTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GTS stands at 0. In comparison, ALHC has a market cap of 4.3B. Regarding current trading prices, GTS is priced at $35.99, while ALHC trades at $21.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GTS currently has a P/E ratio of 10.41, whereas ALHC's P/E ratio is -190.41. In terms of profitability, GTS's ROE is +0.07%, compared to ALHC's ROE of -0.00%. Regarding short-term risk, GTS is less volatile compared to ALHC. This indicates potentially lower risk in terms of short-term price fluctuations for GTS.Check ALHC's competition here

GTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GTS stands at 0. In comparison, CLOV has a market cap of 1.3B. Regarding current trading prices, GTS is priced at $35.99, while CLOV trades at $2.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GTS currently has a P/E ratio of 10.41, whereas CLOV's P/E ratio is -14.79. In terms of profitability, GTS's ROE is +0.07%, compared to CLOV's ROE of -0.26%. Regarding short-term risk, GTS is less volatile compared to CLOV. This indicates potentially lower risk in terms of short-term price fluctuations for GTS.Check CLOV's competition here

GTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GTS stands at 0. In comparison, BHG has a market cap of 130.5M. Regarding current trading prices, GTS is priced at $35.99, while BHG trades at $16.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GTS currently has a P/E ratio of 10.41, whereas BHG's P/E ratio is -0.12. In terms of profitability, GTS's ROE is +0.07%, compared to BHG's ROE of -0.70%. Regarding short-term risk, GTS is less volatile compared to BHG. This indicates potentially lower risk in terms of short-term price fluctuations for GTS.Check BHG's competition here

GTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GTS stands at 0. In comparison, CABR has a market cap of 17.5M. Regarding current trading prices, GTS is priced at $35.99, while CABR trades at $1.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GTS currently has a P/E ratio of 10.41, whereas CABR's P/E ratio is -2.59. In terms of profitability, GTS's ROE is +0.07%, compared to CABR's ROE of -3.00%. Regarding short-term risk, GTS is less volatile compared to CABR. This indicates potentially lower risk in terms of short-term price fluctuations for GTS.Check CABR's competition here

GTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GTS stands at 0. In comparison, BMGL has a market cap of 11.5M. Regarding current trading prices, GTS is priced at $35.99, while BMGL trades at $0.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GTS currently has a P/E ratio of 10.41, whereas BMGL's P/E ratio is -1.36. In terms of profitability, GTS's ROE is +0.07%, compared to BMGL's ROE of -1.95%. Regarding short-term risk, GTS is less volatile compared to BMGL. This indicates potentially lower risk in terms of short-term price fluctuations for GTS.Check BMGL's competition here

GTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GTS stands at 0. In comparison, MRAI has a market cap of 5.6M. Regarding current trading prices, GTS is priced at $35.99, while MRAI trades at $0.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GTS currently has a P/E ratio of 10.41, whereas MRAI's P/E ratio is -0.11. In terms of profitability, GTS's ROE is +0.07%, compared to MRAI's ROE of +0.52%. Regarding short-term risk, GTS is less volatile compared to MRAI. This indicates potentially lower risk in terms of short-term price fluctuations for GTS.Check MRAI's competition here

GTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GTS stands at 0. In comparison, NIVF has a market cap of 1.1M. Regarding current trading prices, GTS is priced at $35.99, while NIVF trades at $1.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GTS currently has a P/E ratio of 10.41, whereas NIVF's P/E ratio is 0.05. In terms of profitability, GTS's ROE is +0.07%, compared to NIVF's ROE of +0.33%. Regarding short-term risk, GTS is less volatile compared to NIVF. This indicates potentially lower risk in terms of short-term price fluctuations for GTS.Check NIVF's competition here

GTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GTS stands at 0. In comparison, AET has a market cap of 0. Regarding current trading prices, GTS is priced at $35.99, while AET trades at $106.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GTS currently has a P/E ratio of 10.41, whereas AET's P/E ratio is N/A. In terms of profitability, GTS's ROE is +0.07%, compared to AET's ROE of +0.11%. Regarding short-term risk, GTS is more volatile compared to AET. This indicates potentially higher risk in terms of short-term price fluctuations for GTS.Check AET's competition here

GTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GTS stands at 0. In comparison, MGLN has a market cap of 0. Regarding current trading prices, GTS is priced at $35.99, while MGLN trades at $94.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GTS currently has a P/E ratio of 10.41, whereas MGLN's P/E ratio is 8.49. In terms of profitability, GTS's ROE is +0.07%, compared to MGLN's ROE of +0.00%. Regarding short-term risk, GTS is more volatile compared to MGLN. This indicates potentially higher risk in terms of short-term price fluctuations for GTS.Check MGLN's competition here

GTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GTS stands at 0. In comparison, UAM has a market cap of 0. Regarding current trading prices, GTS is priced at $35.99, while UAM trades at $1.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GTS currently has a P/E ratio of 10.41, whereas UAM's P/E ratio is N/A. In terms of profitability, GTS's ROE is +0.07%, compared to UAM's ROE of +0.17%. Regarding short-term risk, GTS is more volatile compared to UAM. This indicates potentially higher risk in terms of short-term price fluctuations for GTS.Check UAM's competition here